Advantages of genomic complexity: Bioinformatics opportunities in microRNA cancer signatures

Journal of the American Medical Informatics Association

Volumn 19, Issue 2, 2012, Pages 156-160

  Lussier, Yves A ^a,b,c   Stadler, Walter M ^c   Chen, James L ^c  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; SMALL INTERFERING RNA; TRANSCRIPTOME;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ARTICLE; BASE PAIRING; BIOINFORMATICS; CARCINOGENESIS; GENE EXPRESSION PROFILING; HISTOLOGY; MICROARRAY ANALYSIS; NEOPLASM; PROTEIN PROCESSING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA ISOLATION; RNA SEQUENCE; RNA STABILITY; RNA STRUCTURE; TISSUE SECTION;

COMPUTATIONAL BIOLOGY; GENE EXPRESSION PROFILING; GENETIC MARKERS; GENOMICS; HUMANS; MICRORNAS; NEOPLASMS;

EID: 84863168143     PISSN: 10675027     EISSN: 1527974X     Source Type: Journal    
DOI: 10.1136/amiajnl-2011-000419     Document Type: Article

References (45)

1. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-11.
2. Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011;39:D152-7.
3. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008;26:462-9.
4. Barroso-delJesus A, Romero-Lopez C, Lucena-Aguilar G, et al. Embryonic stem cell-specific miR302-367 cluster: human gene structure and functional characterization of its core promoter. Mol Cell Biol 2008;28:6609-19.
5. Hutvagner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. Science 2002;297:2056-60.
6. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009;10:704-14.
7. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20.
8. Friedman RC, Farh KK, Burge CB, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
9. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010;9:775-89.
10. Lee Y, Yang X, Huang Y, et al. Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. PLoS Comput Biol 2010;6:e1000730.
11. Futreal PA, Coin L, Marshall M, et al. A census of human cancer genes. Nat Rev Cancer 2004;4:177-83.
12. Masuda N, Ohnishi T, Kawamoto S, et al. Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucleic Acids Res 1999;27:4436-43.
13. Xi Y, Nakajima G, Gavin E, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007;13:1668-74.
14. Schuster C, Budczies J, Faber C, et al. MicroRNA expression profiling of specific cells in complex archival tissue stained by immunohistochemistry. Lab Invest 2011;91:157-65.
15. Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010;56:1733-41.
16. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-18.
17. Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A 2011;108:3713-18.
18. Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010;127:118-26.
19. Blenkiron C, Goldstein LD, Thorne NP, et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007;8:R214.
20. Gutierrez NC, Sarasquete ME, Misiewicz-Krzeminska I, et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010;24:629-37.
21. Denis L, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 1993;72:3888-95.
22. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
23. Chen J, Li J, Stadler WM, et al. Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence. J Am Med Inform Assoc 2011;18:392-402.
24. Davis CA, Gerick F, Hintermair V, et al. Reliable gene signatures for microarray classification: assessment of stability and performance. Bioinformatics 2006;22:2356-63.
25. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005;365:488-92.
26. Massague J. Sorting out breast-cancer gene signatures. N Engl J Med 2007;356:294-7.
27. Chen Y, Gelfond JA, McManus LM, et al. Reproducibility of quantitative RT-PCR array in miRNA expression profiling and comparison with microarray analysis. BMC Genomics 2009;10:407.
28. Canales RD, Luo Y, Willey JC, et al. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol 2006;24:1115-22.
29. Benjamini Y, Hochberg Y. On the adaptive control of the false discovery rate in multiple testing with independent statistics. J Educ Behav Stat 2000;25:60-83.
30. Kirk R. Experimental Design: Procedure for Behavioral Science. 2nd edn. Belmont, CA: Brooks/Cole, 1982.
31. Chen J, Sam L, Huang Y, et al. Protein interaction network underpins concordant prognosis among heterogeneous breast cancer signatures. J Biomed Inform 2010;43:385-96.
32. Bozic I, Antal T, Ohtsuki H, et al. Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A 2010;107:18545-50.
33. Bignell GR, Greenman CD, Davies H, et al. Signatures of mutation and selection in the cancer genome. Nature 2010;463:893-8.
34. McKusick VA. Mendelian inheritance in man and its online version, OMIM. Am J Hum Genet 2007;80:588-604.
35. Backes C, Meese E, Lenhof HP, et al. A dictionary on microRNAs and their putative target pathways. Nucleic Acids Res 2010;38:4476-86.
36. Betel D, Koppal A, Agius P, et al. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol 2010;11:R90.
37. Betel D, Wilson M, Gabow A, et al. The microRNA.org resource: targets and expression. Nucleic Acids Res 2008;36:D149-53.
38. Lujambio A, Calin GA, Villanueva A, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 2008;105:13556-61.
39. Wu L, Zhou H, Zhang Q, et al. DNA methylation mediated by a microRNA pathway. Mol Cell 2010;38:465-75.
40. Ciaccio MF, Wagner JP, Chuu CP, et al. Systems analysis of EGF receptor signaling dynamics with microwestern arrays. Nat Methods 2010;7:148-55.
41. Brusniak MY, Kwok ST, Christiansen M, et al. ATAQS: A computational software tool for high throughput transition optimization and validation for selected reaction monitoring mass spectrometry. BMC Bioinformatics 2011;12:78.
42. Yang JH, Li JH, Shao P, et al. starBase: a database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data. Nucleic Acids Res 2011;39:D202-9.
43. Dudley JT, Pouliot Y, Chen R, et al. Translational bioinformatics in the cloud: an affordable alternative. Genome Med 2010;2:51.
44. Ashley EA, Butte AJ, Wheeler MT, et al. Clinical assessment incorporating a personal genome. Lancet 2010;375:1525-35.
45. Mitra R, Bandyopadhyay S, Maulik U, et al. SFSSClass: an integrated approach for miRNA based tumor classification. BMC Bioinformatics 2010;11(Suppl 1):S22.